Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis

Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta-analysis

(2021) Miao Liu et al.   BREAST CANCER RESEARCH AND TREATMENT

Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy

(2021) Jenny Furlanetto et al.   EUROPEAN JOURNAL OF CANCER

Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence

(2021) Milos Holanek et al.   Cancers

Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer

(2021) Maitri Kalra et al.   npj Breast Cancer

Transcription factor KLF2 enhances the sensitivity of breast cancer cells to cisplatin by suppressing kinase WEE1

(2021) Ruiqing Li et al.   CANCER BIOLOGY & THERAPY

Comparative Assessment of Diagnostic Homologous Recombination Deficiency–Associated Mutational Signatures in Ovarian Cancer

(2021) Zsofia Sztupinszki et al.   CLINICAL CANCER RESEARCH

Platinum-based chemotherapy in early-stage triple negative breast cancer: A meta-analysis

(2021) Ramy R. Saleh et al.   CANCER TREATMENT REVIEWS

Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance

(2021) Desh Deepak Singh et al.   Biomedicines

TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial)

(2020) Nadine Tung et al.   JOURNAL OF CLINICAL ONCOLOGY

TBCRC 030: A phase II study of preoperative cisplatin vs. paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker

(2020) E.L. Mayer et al.   ANNALS OF ONCOLOGY

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)

(2020) P.A. Fasching et al.   ANNALS OF ONCOLOGY

Phase II Trial of Neoadjuvant Carboplatin and Nab‐Paclitaxel in Patients with Triple Negative Breast Cancer

(2020) Yuan Yuan et al.   ONCOLOGIST

Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP)

(2020) Priyanka Sharma et al.   CLINICAL CANCER RESEARCH

Homologous recombination deficiency in breast cancer: Implications for risk, cancer development, and therapy

(2020) Rayhaan M. M. Ali et al.   GENES CHROMOSOMES & CANCER

Most neoadjuvant chemotherapy for triple-negative breast cancer should include platinum

(2020) Rebecca Dent et al.   LANCET ONCOLOGY

Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO)

(2019) Christel Fontaine et al.   BREAST CANCER RESEARCH AND TREATMENT

β-hCG-induced mutant BRCA1 ignites drug resistance in susceptible breast tissue

(2019) Satheesh Kumar Sengodan et al.   CARCINOGENESIS

Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM)

(2019) Maria Vittoria Dieci et al.   Cancers

Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history

(2018) Christoph Engel et al.   BMC CANCER

Evaluation of tolerability and efficacy of incorporating carboplatin in neoadjuvant anthracycline and taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohort

(2018) Tal Sella et al.   BREAST

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

(2018) Sibylle Loibl et al.   LANCET ONCOLOGY

Biomarker Assessment of HR Deficiency, TumorBRCA1/2Mutations, andCCNE1Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy

(2018) Euan A. Stronach et al.   MOLECULAR CANCER RESEARCH

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

(2018) Andrew Tutt et al.   NATURE MEDICINE

Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC.

(2018) Melinda L. Telli et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto

(2018) S Loibl et al.   ANNALS OF ONCOLOGY

Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer

(2017) Eric Hahnen et al.   JAMA Oncology

Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer

(2016) Juan Zhang et al.   BREAST CANCER RESEARCH AND TREATMENT

Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts

(2016) Priyanka Sharma et al.   CLINICAL CANCER RESEARCH

Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579)

(2015) Virginia G. Kaklamani et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation–Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105

(2015) Melinda L. Telli et al.   JOURNAL OF CLINICAL ONCOLOGY

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

(2014) Patricia Cortazar et al.   LANCET

Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort

(2013) Rachel Greenup et al.   ANNALS OF SURGICAL ONCOLOGY

Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)

(2012) N. Mavaddat et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer

(2011) Anne-Renee Hartman et al.   CANCER

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

(2010) Daniel P. Silver et al.   JOURNAL OF CLINICAL ONCOLOGY

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

(2008) Cornelia Liedtke et al.   JOURNAL OF CLINICAL ONCOLOGY